EZH2 and breast cancer: -EGCG mediated epigenetic induction of TIMP-3 (tissue inhibitor of matrix metalloproteinase-3) levels and play a key role in suppressing invasiveness and gelatinolytic activity of MMP-2 and MMP-9 in breast cancer cells-Induced TIMP-3 mRNA and protein levels-Reduced the enhancer of zeste homolog 2 (EZH2) and class I HDAC protein levels⇒ EGCG treatment decreased EZH2 catalyzed trimethylation of Histone H3 at Lysine 27 (H3K27me3) with a corresponding increase in the deposition of transcriptionally-active acetylated Histone H3 at Lysine 9/18 (H3K9/18 Ac), specifically at the TIMP-3 promoter